DARE
FOR
MORE ®
FOR
MORE ®
We dare for more in every aspect of what we do – advancing our portfolio of precision therapies for central nervous system disorders – to make the impossible possible.
The field of neurology has been primed for a revolution in how new therapies are discovered. We have taken the charge to develop them.
Our PURPOSE
We come to work every single day with a drive to create lasting impact for humans in need.
About Us
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance.
Praxis is the process of using a theory or learning in a practical way. It is the mindset that allows us to simplify the complex and independently define a solution without being restricted by predefined processes.
Our Expanded Access Policy
Our Approach
Each of our programs is based on four key principles that we believe will both increase the probability of success and allow us to efficiently translate insights into high-impact therapies:
Genetics
Focus on therapeutic targets identified through human genetics.
Translational Tools
Utilize translational tools to validate the potential of our targets and product candidates and potentially provide early proof of biology.
Patient-Guided
Apply patient-guided development strategies to deliver on what patients actually need.
Efficient & Rigorous
Pursue efficient, rigorous clinical development paths to proof-of-concept in humans.
Current Developmental Pipeline
Developing Treatments Inspired by the Genetics of Epilepsy
Enabled by Two Platforms
Four clinical stage assets and multitude of early-stage programs
Leadership Team
We have attracted a talented team of scientists and researchers in genetics and biology, chemistry and translational medicine as well as business leaders with established track records of successfully executing innovative drug discovery and development programs.
Marcio Souza
President & Chief Executive Officer
Steve Petrou
Co-Founder & Chief Scientific Officer
Alyssa Wyant
Chief Regulatory & Quality Officer
Tim Kelly
Chief Financial Officer
Kelly McCue
Chief People Officer
Karl Hansen
Chief Technical Operations Officer
Board of Directors
Dean Mitchell
Chairman of the Board
Dr. Merit Cudkowicz
Director
William Young
Director
Greg Norden
Director
Scientific Advisory Board
Matt Might
CHAIRMAN OF THE SCIENTIFIC ADVISORY BOARD
Anna Greka
Member
Holger Lerche
Member
Ivan Soltesz
Member
Sam Berkovic
Member
Careers
Our mission is to help patients by delivering life-altering treatments faster and more effectively than has ever been done before. Agnostic to the source of an idea, we work together to find the most practical solutions for patients as quickly and efficiently as possible. We need talented and motivated individuals to make this happen.
Building Together
At Praxis we are all involved in building the company together and each employee has an impact. We are challenged to question each other and our own assumptions to deliver treatments for patients and caregivers.
Caring with Candor
As a team-based organization we show care for each other by giving and receiving candid feedback. We support curiosity and ownership for all aspects of our business. This environment fuels our growth and propels us forward.
Passion & Persistence
The work we do is demanding. Praxons are passionate and persistent about transforming neuroscience because of the incredible need to positively change the lives of patients with CNS disorders.
DARE FOR MORE™
We DARE FOR MORE™ in every aspect of our journey, from the patients we are working for, to the portfolio we build and advance every day.
We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders.